Eesti - eesti - Ravimiamet

ideal trade links uab - ampitsilliin+sulbaktaam - süste-/infusioonilahuse pulber - 2000mg+1000mg 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Eesti - eesti - Ravimiamet

ideal trade links uab - ampitsilliin+sulbaktaam - süste-/infusioonilahuse pulber - 1000mg+500mg 1tk

Eesti - eesti - Ravimiamet

ideal trade links uab - paroksetiin - õhukese polümeerikattega tablett - 20mg 14tk; 20mg 30tk; 20mg 28tk

Eesti - eesti - Ravimiamet

kalceks as - esketamiin - süste-/infusioonilahus - 5mg 1ml 5ml 10tk; 5mg 1ml 5ml 5tk

Eesti - eesti - Ravimiamet

auxilia pharma oÜ - ampitsilliin+sulbaktaam - süste-/infusioonilahuse pulber - 1000mg+500mg 1tk

Eesti - eesti - Ravimiamet

laboratorios basi industria farmaceutica s.a. - metoklopramiid - süste-/infusioonilahus - 5mg 1ml 2ml 50tk

Eesti - eesti - Ravimiamet

auxilia pharma oÜ - ampitsilliin+sulbaktaam - süste-/infusioonilahuse pulber - 2000mg+1000mg 1tk; 2000mg+1000mg 10tk

Eesti - eesti - Ravimiamet

baxter holding b.v. - lidokaiin - süstelahus - 20mg 1ml 5ml 10tk; 20mg 1ml 2ml 25tk; 20mg 1ml 5ml 25tk; 20mg 1ml 2ml 5tk; 20mg 1ml 5ml 5tk; 20mg 1ml 20ml 10tk

Eesti - eesti - Ravimiamet

baxter holding b.v. - lidokaiin - süstelahus - 10mg 1ml 10ml 5tk; 10mg 1ml 2ml 5tk; 10mg 1ml 5ml 10tk; 10mg 1ml 10ml 10tk; 10mg 1ml 2ml 10tk; 10mg 1ml 20ml 1tk